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Abstract
Background: Advanced colorectal cancer (CRC), either locally advanced, metastasized (mCRC) or both, is present in
a relevant proportion of patients. The chances on curation of advanced CRC are continuously improving with
modern multi-modality treatment options. For incurable CRC the focus lies on palliation of symptoms, which is not
necessarily a resection of the primary tumor. Both situations motivate adequate staging before treatment in CRC.
This prospective observational study evaluates the outcomes after the introduction of routine staging with
abdominal CT before treatment.
Methods: In a prospective observational study of 612 consecutive patients (2007-2009), the ability of abdominal CT
to find liver metastases (LM), peritoneal carcinomatosis (PC) and T4 stage in colon cancer (CC) was analysed.
Results: Advanced CRC was present in 58% of patients, mCRC in 31%. The ability to find LM was excellent (99%),
cT4 stage CC good (86%) and PC poor (33%). In the group of surgical patients with emergency presentations, the
incidences of both mCRC (51%) and locally advanced colon cancer (LACC) (69%) were higher than in the elective
group (20% and 26% respectively). Staging tended to be omitted more often in the emergency group (35% versus
12% in elective surgery).
Conclusions: The strengths of staging with abdominal CT are to find LM and LACC, however it fails in diagnosing
PC. On grounds of the incidence of advanced CRC, staging is warranted in patients with emergency presentations
as well.
Background
Advanced colorectal carcinoma (CRC), defined as locally
advanced or metastasized disease or both, is present in a
relevant proportion of patients diagnosed with colorectal
cancer. Common localizations for distant metastases are
the liver, the peritoneal cavity and the lung. Staging
with chest CT as a routine procedure before surgery has
not shown to be of clinical benefit, mainly due to the
low incidence of clinically relevant lung metastases and
low specificity of chest CT [1-3]. Pre-operative staging
with abdominal CT might be beneficial when the ability
to detect advanced CRC is high enough and the findings
offer information that may change the treatment plan.
Such findings include liver metastases (LM), peritoneal
carcinomatosis (PC) and locally advanced colon cancer
(LACC). In the past, these conditions were frequently
regarded as incurable and suitable for palliative mea-
sures only. Nowadays various multi-modality treatments
offer a chance of cure to selected patients [4-15]. For
patients with incurable advanced CRC, alternative
options are sometimes available and staging may change
the treatment plan towards the ‘best palliative care’,t h a t
may consist of avoidance of surgery in selected patients
[16-18]. At the present, adequate staging with CT before
treatment is already considered as the standard in inter-
national CRC guidelines. However the evidence for this
advice in literature is mostly limited to studies focused
on the radiological accuracy and also are usually
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ings of staging after implementation of such guideline
has not been described before. An observational study
may be helpful in the debate on actual clinical relevance
and provide lead points to optimize staging in clinical
practice.
The aim of this study is to describe the outcomes of
routine staging with abdominal CT in a unselected hos-
pital population (n = 612) after the introduction of a
regional guideline recommendation in 2007.
Methods
The data were collected in the Medical Spectrum
Twente, a large community teaching hospital in the
regional capital of a foremost rural area in the eastern
part of the Netherlands. It functions as a regional
referral center for liver and lung surgery, but has no
facilities for the treatment of peritoneal carcinomatosis
with hyperthermic intraperitoneal chemotherapy
(HIPEC).
The study design is a prospective observational cohort
study evaluating the outcome of routine staging with
abdominal CT concerning the ability to find liver metas-
tases (LM), peritoneal carcinomatosis (PC) and T4-stage
in colon cancer (LACC). All patients in our hospital
who where treated for CRC from January 2007 till
December 2009 were included in the analysis; all surgi-
cal patients with CRC in the study hospital were pro-
spectively registered in a database designed for
colorectal surgery, including patient characteristics, sta-
ging and surgical procedures, the clinical M stage and
pathological TNM stage, post-operative mortality, treat-
ment of metastases and follow-up; patients with the
diagnosis of CRC in the same 3 years who did not
undergo surgery were identified by the regional cancer
registry and retrospectively added to the database. The
clinical T stage of colon cancer on abdominal CT (cT4
or non-cT4) was retrospectively scored based upon the
original radiology reports.
Routine pre-operative staging with a CT of chest and
abdomen for patients with CRC was introduced as a
regional CRC guideline in 2007 and preceded similar
national guideline recommendations (2008). CT scan-
ning was performed on a 16 and 64 slice scanner
(Toshiba Aquillion 16 and 64) after intravenous contrast
injection (visipaque 320, 90 ml, 3 ml/s.) in the portal
venous phase, with a slice thickness of 1 mm and a
reconstruction of 0.8 mm. When preoperative scanning
was omitted, staging with abdominal CT was intended
within 3 months after surgery. Patients with rectal can-
cer, defined as localization below the peritoneal reflec-
tion, were additionally staged with a pelvic MRI for
determination of the local invasion and possible lymph
node metastases (cTN stage) and received neo-adjuvant
(chemo)radiation according to the Dutch guidelines on
rectal cancer. Follow-up after curative treatment of non-
metastatic CRC consisted of serum CEA measurements
every 3 months combined with bi-annual ultrasound of
the liver.
Pathological staging was based upon the TNM classifi-
cation 2002 (6th edition) and classified according to the
American Joint Committee on Cancer (AJCC) stages.
Advanced CRC was defined as either locally advanced
disease, presence of distant metastases or both. Locally
advanced colon cancer (LACC) was defined by pT4
stage; meaning the tumor showed invasion through the
serosal layer or into surrounding organs. Locally
advanced rectal cancer (LARC) was defined as all
patients that had either a T4 tumor or a T3 tumor with
a threatened circumferential margin on pelvic MRI. The
final diagnosis of liver metastases was based upon radi-
ological (CT, contrast-enhanced ultrasound and/or PET
scanning) and per-operative findings. In case of resec-
tion or in case of persistent uncertainty, histological
confirmation was obtained. The final diagnosis of perito-
neal carcinomatosis was by histological confirmation.
The final diagnosis of lung lesions was on radiological
grounds (chest CT). In case of resection or indetermi-
nate lung lesions, histological confirmation was obtained
when feasible. Several lung lesions remained indetermi-
nate: these were followed by repeat CT scanning and
considered positive when growth was observed [3].
Incurable CRC was defined as all macroscopical irradical
(R2) resections of the primary tumor, when the patient
had no resection of the primary tumor, or when no
intended curative treatment of distant metastases was
done.
Emergency presentation in the surgical patients was
defined as all non-planned admissions to the hospital
due to symptoms related to the tumor, with a subdivi-
sion into ‘urgent’ defined as surgery imperative within 5
days and ‘acute’ procedures within 6 hours.
The ability of the staging abdominal CT to detect
advanced disease was analyzed in surgical patients that
were staged with CT before treatment; the gold standard
for PC and LACC were per-operative findings confirmed
with histology. For LM the findings on CT (negative for
liver metastases or indeterminate lesions) were related
to per-operative findings and follow-up.
Results
In a 3 year period (2007-2009), 612 patients were diag-
nosed with colorectal carcinoma in the study center.
Staging with abdominal CT before treatment was done
in 513 patients (84%). Surgery, either palliative or cura-
tive, was performed in 551 patients (90%). The propor-
tion of surgical patients with an emergency presentation
was 21% (115/551).
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(Figure 1 and Table 1)
Metastatic CRC (mCRC) was diagnosed in 188 patients
(31%). Most common sites of distant metastases were
the liver (n = 144, 24%), peritoneal cavity (n = 49, 8%)
and the lung (n = 42, 7%). Intended curative treatment
of metastases was feasible in 15% of patients with
mCRC (n = 28). Locally advanced disease was present in
262 patients (43%); on the total CRC population the
incidence of LARC was 13% (n = 81) and of LACC was
30% (n = 181). Incurable disease was present in 188
patients (31%), mainly due to mCRC (n = 160).
Finding mCRC and/or LACC on abdominal CT (Table 2)
The cohort of surgical patients that were staged before
treatment (n = 463) was analyzed on the ability of the
abdominal CT to find advanced disease. In this group,
86 patients had liver metastases; in 73 patients (85%)
diagnosed and in 19 patients (14%) suspected (indeter-
minate lesions) on the initial staging CT. The
Colorectal cancer
612 patients
Advanced CRC
358 patients (58%)
Common CRC 
254 patients (42%)
Incurable disease 
188 (31%)
Curatively treated 
170 (28%)
M0
Colon (218)
Rectum (36)
LA-M0
LACC (7)
LARC (1)
LA-M0
LACC (78)
LARC (64)
M1
Colon (32)
Rectum (3)
M1*
Colon (14)
Rectum (4)
LA-M1
LACC + M  (70)
LARC + M (14)
No surgery
M1(41) / Mx (10) / M0 (10)
Rectum (14) / Colon (47)
LA-M1*
LACC + M (8)
LARC + M (2)
Figure 1 Colorectal cancer stage and treatment entire cohort. LA: locally advanced tumors (clinical on staging and/or pathological). M1:
metastastic CRC. M0: no regional or distant metastases. LACC: locally advanced colon carcinoma = pT4 according to TNM 2002 (6th edition).
LARC: locally advanced rectum carcinoma = T4 tumors and T3 tumor with threatened circumferential margin on MRI. *Curative treatment distant
metastases in 28 patients: liver 24, peritoneal 2, lung 2.
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additional diagnostic testing, which were contrast-
enhanced ultrasound, positron emission tomography
(PET), PET/CT or MRI. In 12 patients the indetermi-
nate lesions were diagnosed as metastases and in 7
patients as benign lesions; of these, 6 patients had a fol-
low-up of more then one year including imaging of the
liver, and none was diagnosed with metastases. In one
patient the liver metastasis was not seen nor suspected
on CT, but found during surgery. The ability of the sta-
ging CT to detect liver metastases, summating diagnosis
on CT and with additional imaging for indeterminate
lesions, was 99%. Peritoneal carcinomatosis was diag-
nosed in 33 patients; in 11 patients prior to surgery on
the staging CT (33%), in the remaining 22 patients these
were found during surgery for the primary tumor.
LACC was correctly suggested in 99 out of 115 patients
(86%).
In surgical patients with LACC (n = 160), the inci-
dence of mCRC was 45% (n = 73); PC was present in 38
patients (24%) and LM in 46 patients (29%). Of the 41
surgical patients with PC, 38 patients had LACC (93%).
Emergency presentation in surgical patients
In surgical patients with an emergency presentation (n =
115), the incidence of mCRC was 51% (n = 59) versus
20% in the elective group (88/436). In the same group,
limited to colon cancer patients (n = 110), the incidence
of LACC was 69% (n = 76) versus 26% in the elective
group (84 out of 317). Staging was omitted in 35 out of
115 patients with an emergency presentation (30%), ver-
sus 53 out of 436 elective surgical patients (12%).
Discussion and Conclusions
Advanced CRC is common, occurring in 58% of CRC
patients in the study. It raises little question at the pre-
sent that staging before treatment is required. It is pre-
sumed the abdominal CT can accurately identify the
patients with advanced CRC. For liver metastases and
LACC the abdominal CT indeed is an adequate first-
line imaging technique, however for PC it grossly lacks
Table 1 Characteristics all patients with CRC 2007-2009
All patients (n = 612)
Age
Mean 70 yr
Median 70 yr
Range 33-98 yr
Gender
Male 349 57%
Female 263 43%
Localization primary tumor
Colon 474 77%
Rectum 138 23%
Staging procedure
Abdominal CT preceding treatment 513 84%
Abdominal CT < 3 months after surgery 44 7%
AJCC stage based on pTNM (2002)
a
Stage 0 12 2%
Stage I 75 12%
Stage II 171 28%
Stage III 143 23%
Stage IV 188 31%
Not classified
d 23 4%
Localizations of distant metastases in cohort
b
Liver 101 17%
Peritoneal 27 4%
Liver and lung 24 4%
Liver and peritoneal 11 2%
Lung 7 1%
Peritoneal and lung 4 1%
More than 2 organs and/or other localisations
c 14 2%
Localization of distant metastases per organ
b, c
Liver 144 24%
Peritoneal 49 8%
Lung 42 7%
a This includes patients with pathological downstaging after neoadjuvant
chemoradiation (n = 69); a complete remission of histologically proven
colorectal cancer was staged as stage 0.
b Staging of the lung in this cohort was done with chest CT (n = 415) or chest
X-ray (n = 197).
c Other localisations were brain and skeletal metastases.
d Of 23 patients, 20 patients had no surgery and 3 patients had no resection
resulting in an unknown TN status. Of 23 patients, 11 patients had an
unknown M status and 12 patients had M0 status.
Table 2 Detection advanced CRC on abdominal CT
Analysis of surgical patients that were staged before treatment (n = 463)
Diagnosed Suspected Not
seen
Liver metastases n = 86 73 85% 12 14% 1 1%
Peritoneal
carcinomatosis
n = 33 11 33% 6 18% 16 48%
pT4 colon carcinoma
a n = 115 99 86% 5 4% 11 10%
Rectum (n = 115) Colon (n = 348)
cM pM cM pM
n% n % n % n %
Liver metastases 13 11% 16 14% 61 18% 70 20%
Peritoneal
carcinomatosis
2 2% 3 3% 9 3% 30 9%
Locally advanced
disease
n.a.
b n.a. 99 29% 123 36%
cM: metastases diagnosed before treatment on staging abdominal CT
(without additional diagnostics)
pM: final conclusion, including additional imaging, peroperative findings and
histology
a In 8 patients the local invasiness was not described in the original report,
leaving 115 patients for evaluation
b Local invasiveness and lymph node status (cTN stage) in rectal carcinoma
was determined on pelvic MRI
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and PC, LACC may serve as a warning sign for the pos-
s i b l ep r e s e n c eo fP C .T h ei n c i d e n c eo fa d v a n c e dC R C
was especially high in patients with emergency presenta-
tions, while staging tended to be omitted more often in
this group.
T h ep r e s e n ts t u d yw a sd o n ei nas i n g l eh o s p i t a la n d
therefore has a limited number of patients as com-
pared to true population-based studies. The additive
value of this analyses is the prospective design, that is
inherently more accurate and provides more detailed
clinical data. The outcomes are expected to represent
population based incidences fairly good, due to the
fact the study was done in an relatively isolated region
in the Netherlands that knows very little referral or
selection bias. In comparison to a large population-
based study from the Netherlands [19] this study
reports a higher incidence of mCRC (colon cancer 34%
vs 25% and rectal cancer 22% vs 24%). This variance in
incidence of mCRC probably has several causes; such
as due to differences in staging routines, mode of data
registration, CT scanning protocols and the adverse
regional socio-economic status.
Considering potentially curable mCRC, the relevance
and outcomes of staging before treatment is most well-
known for liver metastases. Staging with CT before
treatment provides the opportunity to change the treat-
ment strategy; various studies have reported promising
results of alternative approaches in terms of eligibility of
resection and the oncological outcome [10,11,20]. Pre-
vious reports show a high accuracy of CT for liver
metastases, with an initial sensitivity of approximately
85% which is similar in this study [21]. One study con-
cluded that also small and indeterminate liver lesions
should be reported, to optimize the detection rates of
true metastases[22]. Our observations agree with that
conclusion; Indeterminate lesions in the liver were not a
major concern and discrimination of indeterminate liver
lesions with additional imaging caused no major diag-
nostic uncertainties or resources. Contrast-enhanced
abdominal MRI is an equivalent alternative to multi-
slice CT scanning for LM, [23] however may cause
more logistic problems.
Concerning PC, the benefits of staging before treat-
ment are much less outspoken. In the recent past PC
was regarded as a virtually incurable condition with little
treatment options. Therefore accurate staging of PC was
considered less important. This has changed since the
introduction of HIPEC offering a chance for cure in
selected patients [6,12,13]. Since HIPEC is performed in
specialized centers only, accurate pre-operative staging
of PC has become vital to improve the outcome of these
patients. The present study confirms the finding of pre-
vious studies that PC is poorly visualized on a CT scan
[24]. Other imaging techniques may be more sensitive
to detect and estimate the extent of PC, such as diffu-
sion-weighted imaging (DWI) combined with MRI [25].
This however remains to be proven for its clinical value
in colorectal cancer. An alternate approach may be to
utilize the observed close relationship between PC and
LACC, e.g. by performing a diagnostic laparoscopy in
patients with a cT4 tumor on CT; estimation of T stage
on abdominal CT in this and another study [26] seems
to be fairly reliable.
Standardized radiology reports on T stage in colon
cancer and on localization, sizes, spread and preferably
‘weighed’ suspicion of distant metastases may enhance
the ability to find advanced CRC with the staging
abdominal CT.
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